TITLE

JOHNS HOPKINS DEVELOPS COLON CANCER BLOOD TEST

PUB. DATE
December 2005
SOURCE
Worldwide Biotech;Dec2005, Vol. 17 Issue 12, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on a blood test developed by researchers at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute with Indivumed for the diagnosis of colon cancer. Cancer genes detected in the blood of colorectal cancer patients; Background of Indivumed.
ACCESSION #
18955481

 

Related Articles

  • Early diagnosis of colorectal cancer: a review. Hardcastle, J. D.; Armitage, N. C. // Journal of the Royal Society of Medicine;Aug1984, Vol. 77 Issue 8, p673 

    The article focuses on the study of early diagnosis of colorectal cancer. The detection of occult blood in faeces is at present the only practical method of population screening for colorectal cancer and can be performed using a guaiac-impregnated slide test such as Haemoccult. Its use in...

  • Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme. Castiglione, G.; Visioli, C. B.; Ciatto, S.; Grazzini, G.; Bonanomi, A. G.; Rubeca, T.; Mantellini, P.; Zappa, M. // British Journal of Cancer;6/4/2007, Vol. 96 Issue 11, p1750 

    We evaluated the sensitivity for colorectal cancer (CRC) of the latex agglutination test (LAT), an immunochemical test routinely used in the Florence District screening programme since 2000. Sensitivity was calculated by the proportional interval cancer incidence method in a population of 27 503...

  • Colorectal cancer screening using the faecal occult blood test (FOBt): a survey of GP attitudes and practices in the UK. Damery, Sarah; Clifford, Sue; Wilson, Sue // BMC Family Practice;2010, Vol. 11, p20 

    Background: Colorectal cancer (CRC) is the third most common cancer in the UK. Five-year survival rates are less than 50%, largely because of late diagnosis. Screening using faecal occult blood tests (FOBt) can detect bowel cancer at an earlier stage than symptomatic presentation, and has the...

  • Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Lomholt, A. F.; Høyer-Hansen, G.; Nielsen, H. J.; Christensen, I. J. // British Journal of Cancer;9/8/2009, Vol. 101 Issue 6, p992 

    Background:Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality in developed countries. It is known that early detection results in improved survival, and consequently there is a need for improved diagnostic tools in CRC. The plasma level of soluble urokinase...

  • Blood tests 'may enhance' colorectal cancer checks. Moberly, Tom // GP: General Practitioner;9/25/2009, p15 

    The article reports that the blood tests related to cancer gene helps improving the detection rates of colorectal cancer in Great Britain. It offers information on two genes including Syne1 and Foxe that are found in cancer patients. According to Joost Louwagie, doctor the test can give better...

  • PSA REVISITED.  // Time;7/19/2004, Vol. 164 Issue 3, p85 

    The article discusses how the link between PSA blood-test results and prostate cancer has seen its share of controversy. A recent study found that some men developed the cancer even when their PSA readings were normal. A new study suggests that it is the rate of increase in a man's PSA level,...

  • HOW MUCH BLOOD IS ENOUGH? AN EVIDENCE-BASED STUDY ON THE MINIMUM BLOOD VOLUME REQUIRED FOR LABORATORY TESTS. Rodriguez, Wanda; McCarty, Doreen; O'Donnell, AnnMarie; Kane, Joyce; Nolan, Stephanie; Carlese, Cristina // Oncology Nursing Forum;Mar2007, Vol. 34 Issue 2, p527 

    Frequent blood sampling for laboratory testing can be an unnecessary source of blood loss in the critically ill oncology patient. The increased number of analytes measured combined with increased frequency in testing and easier collection with arterial and venous catheters can directly lead to...

  • Multi-Target Stool DNA Test: A New High Bar for Noninvasive Screening. Ahlquist, David // Digestive Diseases & Sciences;Mar2015, Vol. 60 Issue 3, p623 

    Stool DNA testing has evolved into what is now a highly accurate and well-validated test for the screen detection of colorectal neoplasia. An optimized and automated multi-target stool DNA test (MT-sDNA) has achieved the same high point-sensitivities as reported for colonoscopy and significantly...

  • Enzo Biochem Launch of Test for Measuring Risk of Colorectal Cancer Underscores Growing Role of Molecular Diagnostics.  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article informs that Enzo Biochem Inc. has launched the ColonSentry test for assessing a patient's risk of having colorectal cancer. ColonSentry is a first of its kind blood-based risk stratification test for colorectal cancer. The test utilizes RNA to measure the level of expression of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics